Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients


This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.

Full Title of Study: “Development and Persistence of Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients in Comparison With Immunocompetent Patients”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 29, 2020

Detailed Description

The liver transplant (HT) recipient population is more susceptible to infections than the general population. Few data are available regarding the incidence and clinical course of SARS-CoV-2 infection in this population, initially considered to be "high risk" regarding a possible higher incidence and severity of infection in these patients. A prospective cohort of liver transplant recipient patients diagnosed with SARS-CoV-2 infection (Clinical Protocol Record HCB / 2020/0384) has been developed from SETH (Spanish Society for Liver Transplantation). This study aims to analyze the incidence and establish the clinical evolution of the infection in these patients. Initial data from the cohort, which includes 111 incidental cases diagnosed as of April 7, show a higher standardized incidence than the general population, but not higher mortality (data being published). The chronic immunosuppression in t solid organ transplant patients could play a double role with respect to SARS-Cov-2 infection: on the one hand, it may condition a greater susceptibility and initial aggressiveness, in relation to itself viral effect, and in the other hand, it could protect by reducing the immune response that triggers the pulmonary and systemic inflammatory process. After the initial Covid-19 outbreak, both in the general population and in immunosuppressed patients, the rate of specific IgM and IgG seroconversion against this coronavirus, and its protective capacity against reactivations or reinfections, are unknown. Therefore, it is a challenge for health organizations to identify the immune response in the population and to characterize its degree of protection, to adopt early measures to lessen the consequences of possible epidemic waves in the coming months. Continuing with the prospective study of the cohort of liver transplant patients diagnosed with Covid-19 (SETH-Covid-19), already defined and composed of 91 living patients, the humoral immune response and its evolution in the first 12 months after initial infection. The cohort will incorporate the new incidental cases; A comparative study will be carried out with a contemporary cohort of non-immunosuppressed patients, controlled for age, gender and severity of the initial disease.


  • Diagnostic Test: CLIA of IgG and IgM against SARS-Cov-2
    • Report of clinical data

Arms, Groups and Cohorts

  • Liver transplant patient after having Covid19
    • Adult Liver transplant patient who had survived to Covid19 in the first wave of the disease in Spain (disease until june 30th), in all the liver Transplant Units in Spain (24).
  • No immunosuppressed patient with previous Covid19
    • Not immunosuppressed patient who had survived to Covid19 in the first wave of the disease. These patient have been diagnosed and treated in the Hospital Gregorio Marañón (Madrid), before 30th June

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of IgG against SARS-CoV-2
    • Time Frame: one year
    • Proportion, Rate

Secondary Measures

  • titration and evolution of humoral response (IgG) along first 12 months after having Covid-19
    • Time Frame: 12 months
    • Titer
  • Reinfection of Covid-19
    • Time Frame: one year
    • Categoric Yes/Not

Participating in This Clinical Trial

Inclusion Criteria

Patients recovered of covid 19 Informed Consent Exclusion Criteria:

Chemotherapy on going Concomitant Autoimmune diseases

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Investigator Details

  • Lead Sponsor
    • Magdalena Salcedo
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Magdalena Salcedo, Attending Physician, Hepatology – Hospital General Universitario Gregorio Marañon
  • Overall Official(s)
    • Magdalena Salcedo, MD PhD, Principal Investigator, Liver Transplantation Unit
  • Overall Contact(s)
    • Magdalena Salcedo, MD PhD, +34609751256,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.